provided operational highlights and outlined expected upcoming milestones. “2024 was a landmark year for 4DMT, driven by groundbreaking clinical advancements toward Phase 3 trials that position ...

These risks are described under the "Risk Factors" section included in Nuvve's most recent Annual Report on Form 10-K and any subsequent quarterly filings on Form 10-Q filed with the Securities ...

A $400 million opportunity over the next 4 years for electrification of over 5,000 fleet vehicles and supporting infrastructure throughout the state The Nuvve contract will address the SONM’s ...

With his first film, writer and director Michiel Blanchart burst onto the scene with Night Call, a nonstop action thriller that follows one unlucky locksmith through the worst night of his life.

its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest ...

In this Healio Video Perspective from SECO 2025, Kristen Brotherson, general manager of U.S. vision care at Alcon, outlined the company’s latest eye care innovations being premiered at the meeting.

today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. "Heading into 2025, Ventyx has established itself as the leader in the field ...

WPL Live Score, Gujarat Giants vs Mumbai Indians Highlights: All-rounder Nat Sciver-Brunt starred in both departments as Mumbai Indians produced a clinical performance to return to winning ways ...

Avidity reported its 2025 outlook, including upcoming clinical and regulatory highlights, and recent organization appointments to execute on the full range of strategic initiatives and growth ...

Recent Highlights Avidity will be reporting top-line del-zota data from the completed Phase 1/2 EXPLORE44 ® trial for people living with Duchenne muscular dystrophy amenable to exon 44 skipping ...

today reported financial results for the fourth quarter and full year 2024 and recent business highlights. “Our most recent clinical data for DYNE-101 from the ACHIEVE trial in DM1 patients showed ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today ...